NUVB Nuvation Bio Inc - Ordinary Shares - Class A

A history of what's happend to the share prices of all 65 new commercial-stage oncology focused bios post FDA approval, back to 1/1/2013 (sorted by PDUFA date). The evidence appears overwhelming shareholder value is maximized via M&A exit, and in 90% of these cases within 2 years of FDA approval. Studies from industry, government & academia looking at thousands of drug development programs over the last 50 years conclude only 95-98% of new cancer drugs in Phase 1 are never approved. This is probably why 95-98% of clinical-stage oncology focused bios fail. Of course there are exceptions $NUVB ? Common sense suggests this space is ripe for consolidation. Everyone wins, including the healthcare community at large via scale to best control costs. $SNDX should be the poster boy for the phenomenon. Had one invested $1,000 in each bio 2 days post approval, the collective investment would be worth $64,775 intra-day 9/28/26. This is not investment advice. The data could be wrong $IMCR $CELC $LEGN

$NUVB This company will fly next year, with the Safu data ! By end of 2027- 2028, the projected future sales will be incorporated in the share price which means 2-4B a year.. Make the math and you ll see how high this will go.. Load now that is cheap.. The new funds that got in 2 months ago , haven't made a penny yet...Together with the short covering, it will make a huge move ! Those opportunities are once in a lifetime!

$NUVB Fellow longs: For almost two years here I have been an openly admitted & biased bull but transparent with my opinions. So often you saw me posting my shares purchases just so you know that I am not bullshit you. And honestly I don’t like to average up but sincerely hope they could dump their shares at $3 or $2 for whatever reason so I don’t have to wait. Been buying lately and Below are catch of the day. You should only do it on your own terms because again only you know best of your financial conditions. Survival first. BLTA

$NUVB Today's news should increase the probability of large tutes and specialty biotech funds building their positions. With NUVB's new label, showing a 49.6 mos median PFS, institutional models can safely project stable multi-yr recurring cash flows from every frontline patient start. Recognize Ibtrozi now has the advantage not only with the label expansion but with NCCN guideline SOC recommendation. This alone erodes GSK's pipeline advantage with large Hospital systems.

$NUVB These huge green closing candles show exactly how manipulated the SP is. Add as many on those dips as you can. This will literally jump a few legs up in Q4.

$NUVB if you don’t think this is intentionally being brought down you need to give your head a shake. Look at the fundamentals. Nothing but good news and reiterated buys and initiated buys from analysts. Nothing has changed for the worse. This is 1000% market manipulation. Funds wanted in lower so they brought it down lower. They wouldn’t do it for you or I but that’s the game I guess.

$NUVB I saw from a link were it says that GSK drug is better than Ibtozi's drug.. Well GSK doesn't show the whole picture as they know IBTROZI is still much better than their drug.. Jideytro's new 94% first-line ORR is excellent and makes it a serious IBTROZI competitor, but it does not establish that Jideytro is the better drug. The Jideytro dataset has 94 TKI-naïve patients and only ~15 months median follow-up, whereas IBTROZI has 157 TKI-naïve patients, 89.8% ORR, 49.7-month median DOR (Meaning roughly half the responding patients were still responding around four years later !!!) and 46.1-month median PFS while the latest TRUST-I dataset was approximately 49.6 months!!! In addition, ARROS-1 excluded patients with known oncogenic drivers other than ROS1, whereas TRUST-I ( Ibtrozi) placed no restriction on concurrent oncogenic driver mutations including oncogenic drivers, making a simple 94% vs 89.8% ORR comparison inappropriate. More in the comments..

$NUVB Guys, don't worry. Nothing has changed here. Doesn't it seem strange to you that it dropped like this for no apparent reason? As our colleague mentioned, perhaps the person who was always manipulating this stock has cashed out. Personally, I believe it’s going to skyrocket—it’s just a matter of when.

$NUVB with an all time high of short interest, can you imaging the volcano if NUVB came out with surprising spectacular news?

$NUVB NUVB (NP)- At Citigroup Biopharma Summit, Nuvation bio highlighted progress for safusidenib in a number of pivotal trials as well as unprecedented 52% response rate at 3 years with 79% non-progression. They are enrolling multiple studies covering all four types of glioma. Vorasidenib had 41% progression at year 2 vs just 12% for safusidenib. Vorasidenib is on about $2 billion annual run rate after just 18 months on the market. They have treated over 5,500 patients, which means 1/4 of those (over 1,000 patients) are progressing or have already progressed (significant need for safusidenib to fill). They intend to pursue a conversation with the FDA on TGR (tumor growth rate) as another endpoint to consider that could come even sooner than response rate. CEO's hope is whether patients have low-grade or high-grade disease, at some point they'll simply start with safusidenib vs switching from vora because the former is clearly a superior agent. They are comfortable on cash (~$700M).

$NUVB NUVB doesn't necessarily need 2,000–3,000 new patients annually to create a billion-dollar drug. If treatment lasts sufficiently long, (40m) 1,200 new patients per year could be enough. 100 new first-line patients every month, and each patient stays on treatment for an average of 40 months( i am not using 50m which they got recently..) , annual U.S. net revenue could approach $1 billion from those first-line patients alone. Using our assumed $245,000 net annual revenue per patient: MATURE ANNUAL REVENUE SCENARIO $980 million/year 100 new patients/month × 40 months of treatment × $245,000 per patient-year. So as i said, give it some time to roll, we are still in the beginning of a beautiful journey.. Right now we are at 50 patients per month.. Patients will stay in Ibtrozi, because it is best in class , with fewer side effects than the others.. We are sitting in a gold mine here, but MM and funds trying their best to hide it from us..

$NUVB An interesting day worth remembering and revisiting later. Close to 15 million shares changed hands without any good or bad news, not in Triple Witching day of 9/18 but some funds picked the 1st Oct Friday to execute this huge volumes targeting a small biotech led by a industry well known founder CEO who sold his last company Medivation for $14 Billions to PFZ 10 yrs ago. Btw Dr Hung owns 60 million shares/RSU so he has $25 M paper losses today & $150+M losses in past 40-day when NUVB reached $7.58 high on 8/19/26. So 100% it caught his attention. The Question is what’s he going to do about it? IMO, the June Offering was a good idea but priced too low so the over hang provided the hedge funds a free bank run for too long. Longs can find my posts using ADPT as the sample to point out that NUVB should’ve been out of the hedge overhang in almost 3-M long. For that I blame all on the CFO Phillips executed poorly and stopped our momentum and hurt us all. Better days ahead.

$NUVB Commercial ramp and international expansion of Ibtrozi, Sigma trial, and DDC platform. Don’t let bears FUD you out of this one

$NUVB Extra averaging UP WITH 2,000 shares 9/11 and yesterday are paying off. Average still just $4.65.🫡

$NUVB Okay great news today 4 months ahead of schedule Now let's go with MHRA approval.

$NUVB Previously at AACR 2026, the pooled analysis of all TKI-naïve patients in the TRUST-I and TRUST-II studies presented showed a confirmed objective response rate (ORR) of 89.8% and a median duration of response (DOR) of 49.7 months. At WCLC, one of the new analyses presented in the poster revealed consistent response rates regardless of prior chemotherapy exposure. Among TKI-naïve patients: ORR was 90.0% in those with prior chemotherapy (n=30) and 89.8% in those with no prior chemotherapy (n=127). Median DOR was 48.3 months and 54.3 months, respectively.

$NUVB the price tape remains bearish because three consecutive down sessions after Friday's heavy-volume break are significant. But today's underlying smart-money indicators are considerably less bearish: volume normalized substantially, dark-pool participation was ordinary, and options flow actually leaned toward calls.

$NUVB Bought some today and waiting for $4.5 ranges for more. It’s day like this OG longs will remember when it’s our time to celebrate. So for now take it easy. Survive first. Every dog has its day. Btw salute to the 200 shares seller at $199,999.00 you’re my inspiration. Lol. And for that 200 shares buyer at $0.001 what can I say? Are you the twins of that seller? Hope both of your dreams come true.

$NUVB just curious. If the price was at $7.30 and I wanted to buy cheaper shares. Would the market makers drop it for me lol

$NUVB how to make money in the market: Step 1 - buy low Step 2 - sell high. We are at Step 1 here. This isn’t something to complain about; it is an opportunity to be excited about.